HL-60Homo sapiens (Human)Cancer cell line
Also known as: HL 60, HL.60, HL60, Human Leukemia-60, IIL-60 (Occasionally.)
Quick Overview
HL-60 is a human leukemia cell line used in cancer research.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_0002 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Peripheral blood[UBERON:UBERON_0000178] |
Donor Information
| Age | 36 |
|---|---|
| Age Category | Adult |
| Sex | Female |
| Race | caucasian |
Disease Information
| Disease | Adult acute myeloid leukemia |
|---|---|
| Lineage | Myeloid |
| Subtype | Acute Myeloid Leukemia |
| OncoTree Code | AML |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000002_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| Gene deletion | TP53 | - | Homozygous | 2 out of 3 copies | from parent cell line HL-60 |
| MutationSimple | CDKN2A | p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T) | Homozygous | - | from parent cell line HL-60 |
| MutationSimple | NRAS | p.Gln61Leu (c.182A>T) | Unspecified | - | PubMed=26214590 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.
Santibanez-Koref M.F., Schlag P.M., Scherneck S.
Genes Chromosomes Cancer 37:29-35(2003).
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Culture of SARS-CoV-2 in a panel of laboratory cell lines, permissivity, and differences in growth profile.
Wurtz N., Penant G., Jardot P., Duclos N., La Scola B.
Eur. J. Clin. Microbiol. Infect. Dis. 40:477-484(2021).
The LL-100 panel: 100 cell lines for blood cancer studies.";
MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.
Sci. Rep. 9:8218-8218(2019).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Establishment of a DeltaF508-CF promyelocytic cell line for cystic fibrosis research and drug screening.
Jennings S., Ng H.P., Wang G.-S.
J. Cyst. Fibros. 18:44-53(2019).
Screening human cell lines for viral infections applying RNA-Seq data analysis.
Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.
PLoS ONE 14:E0210404-E0210404(2019).
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
Yang H.H., Koeffler H.P.
BMC Cancer 18:940.1-940.13(2018).
The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.
Gerstberger T., Zuber J., Savarese F., Kraut N.
Oncogene 37:2687-2701(2018).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene.
Pigazzi M., Martelli A.M., Basso G., Locatelli F., Pession A.
J. Hematol. Oncol. 10:26.1-26.5(2017).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
A mass spectrometric-derived cell surface protein atlas.";
Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.
PLoS ONE 10:E0121314-E0121314(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
PLoS ONE 9:E92047-E92047(2014).
Mechanisms of resistance to azacitidine in human leukemia cell lines.
Ohmine K., Muroi K., Ozawa K.
Exp. Hematol. 42:294-306.e2(2014).
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms.
Haferlach T., Shirahige K., Miyano S., Ogawa S.
Nat. Genet. 45:1232-1237(2013).
The analysis of N-glycans of cell membrane proteins from human hematopoietic cell lines reveals distinctions in their pattern.
Reinke S.O., Bayer M., Berger M., Hinderlich S., Blanchard V.
Biol. Chem. 393:731-747(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.
Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.
PLoS ONE 7:E31628-E31628(2012).
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Ambudkar S.V., Gottesman M.M.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
Microarray analysis of responsible genes in increased growth rate in the subline of HL60 (HL60RG) cells.
Suzuki T.
Mutat. Res. 731:20-26(2012).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mol. Cancer Ther. 5:2606-2612(2006).
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
Leukemia 20:471-476(2006).
Comparison of the complete mtDNA genome sequences of human cell lines -- HL-60 and GM10742A -- from individuals with pro-myelocytic leukemia and Leber hereditary optic neuropathy, respectively, and the inclusion of HL-60 in the NIST human mitochondrial DNA standard reference material -- SRM 2392-I.
Kienker L.J., Williams D.W., Jones M., Richie K.L.
Mitochondrion 2:387-400(2003).
Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.
Fioretos T.
Leukemia 19:1042-1050(2005).
The leukemia-lymphoma cell line factsbook.";
Drexler H.G.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
Heterogeneity of cellular origins in human malignant lymphoma cell line derived from histo-monocytic lineage cells.
Morikawa S., Harada T., Katoh T.
(In book chapter) Cellular, molecular, genetic approaches to immunodiagnosis and immunotherapy. 8th International conference on labeled antibodies, Tokyo, November 1985; Kano K., Mori S., Sugisaki T., Torisu M. (eds.); pp.373-380; Karger; Basel; Switzerland (1988).
Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture.
Collins S.J., Gallo R.C., Gallagher R.E.
Nature 270:347-349(1977).
Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia.
Tsai S., Metzgar R.S., Aulakh G., Ting R., Ruscetti F.W., Gallo R.C.
Blood 54:713-733(1979).
Growth study of lactate and ammonia double-resistant clones of HL-60 cells.
Schumpp-Vonach B., Schlaeger E.-J.
Cytotechnology 8:39-44(1992).
Expression of the polymorphic human DNA repair gene XRCC1 does not correlate with radiosensitivity in the cells of human head and neck tumor cell lines.
Dunphy E.J., Beckett M.A., Thompson L.H., Weichselbaum R.R.
Radiat. Res. 130:166-170(1992).
Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha).
Collins S.J., Robertson K.A., Mueller L.
Mol. Cell. Biol. 10:2154-2163(1990).
Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.
Nakano A., Harada T., Morikawa S., Kato Y.
Acta Pathol. Jpn. 40:107-115(1990).
Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells.
Rosado M., Lutzky J., Bhalla K.N., Baker M.A., Taub R.N.
Cancer Res. 49:4607-4614(1989).
Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells.
Wolf D., Rotter V.
Proc. Natl. Acad. Sci. U.S.A. 82:790-794(1985).
Isoenzyme studies in human leukemia-lymphoma cell lines -- 1. carboxylic esterase.
Drexler H.G., Gaedicke G., Minowada J.
Leuk. Res. 9:209-229(1985).
Isoenzyme studies in human leukemia-lymphoma cell lines -- III. Beta-hexosaminidase (E.C. 3.2.1.30).
Drexler H.G., Gaedicke G., Minowada J.
Leuk. Res. 9:549-559(1985).
The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression.
Collins S.J.
Blood 70:1233-1244(1987).
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Cancer Res. 48:589-601(1988).
HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3.
Stass S.A., Trujillo J.M.
Blood 71:242-247(1988).
Isolation and characterization of an anthracycline-resistant human leukemic cell line.
Bhalla K.N., Hindenburg A.A., Taub R.N., Grant S.
Cancer Res. 45:3657-3662(1985).
Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid phosphatase.
Drexler H.G., Gaedicke G., Minowada J.
Leuk. Res. 9:537-548(1985).
Lineage infidelity of a human myelogenous leukemia cell line.";
Palumbo A., Minowada J., Erikson J., Croce C.M., Rovera G.
Blood 64:1059-1063(1984).
Induction of differentiation in a human promyelocytic leukemic cell line (HL-60). Production of granule proteins.
Olsson I., Olofsson T.
Exp. Cell Res. 131:225-230(1981).
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
A blast subclone of the HL-60 human promyelocytic cell line.";
Major P.P., Griffin J.D., Minden M.D., Kufe D.W.
Leuk. Res. 5:429-430(1981).
Differential expression of the amv gene in human hematopoietic cells.
Aaronson S.A., Wong-Staal F.
Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982).
Human myeloid leukemia cell lines: a review.";
Koeffler H.P., Golde D.W.
Blood 56:344-350(1980).
Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene in cell lines established from children with acute lymphoblastic leukemia.
Findley H.W. Jr.
Leukemia 9:1159-1161(1995).
DNA double-strand break rejoining deficiency in TK6 and other human B-lymphoblast cell lines.
Olive P.L.
Radiat. Res. 134:307-315(1993).
Cell surface c-kit receptors in human leukemia cell lines and pediatric leukemia: selective preservation of c-kit expression on megakaryoblastic cell lines during adaptation to in vitro culture.
Imaizumi M., Endo M., Takano N., Konno T.
Leukemia 10:102-105(1996).
Transfection of wild-type but not mutant p53 induces early monocytic differentiation in HL60 cells and increases their sensitivity to stress.
Bertino J.R.
Cell Growth Differ. 6:1405-1413(1995).
Prolonged weightlessness affects promyelocytic multidrug resistance.
Piepmeier E.H., Kalns J.E., McIntyre K.M., Lewis M.L.
Exp. Cell Res. 237:410-418(1997).
Frameshift mutations of the hMSH6 gene in human leukemia cell lines.
Hirai H.
Jpn. J. Cancer Res. 89:33-39(1998).
Use of the comet test in the evaluation of multidrug resistance of human cell lines.
Mattii L., Barale R., Petrini M.
Leukemia 12:627-632(1998).
Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity.
Danenberg P.V.
Clin. Cancer Res. 4:1315-1322(1998).
The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms.
Takeshita K., Takeshita A., Ohno R.
Leukemia 12:1383-1391(1998).
Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.
Aizawa Y., Ueda R., Seto M.
Jpn. J. Cancer Res. 89:712-718(1998).
Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines.
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Leuk. Res. 24:255-262(2000).
Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000), 255-262.
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Leuk. Res. 25:275-278(2001).
Short tandem repeat profiling provides an international reference standard for human cell lines.
Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.
Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
Anecdotal Information
- Established at the 60th attempt to culture human leukemia biopsies in Gallo's lab. All the preceding attempts having failed